| Product Code: ETC7635359 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The neuroprotective agents import market in Ireland experienced a significant growth spurt in 2024, with top exporting countries being Germany, UK, USA, Canada, and other areas not elsewhere specified. The market concentration, as measured by the Herfindahl-Hirschman Index (HHI), escalated from moderate to high in just one year. The impressive compound annual growth rate (CAGR) of 23.25% from 2020 to 2024 indicates a robust market expansion, further bolstered by a remarkable growth rate of 68.68% from 2023 to 2024. This suggests a flourishing demand for neuroprotective agents and a dynamic market landscape in Ireland.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Ireland Neuroprotective Agents Market Overview |
3.1 Ireland Country Macro Economic Indicators |
3.2 Ireland Neuroprotective Agents Market Revenues & Volume, 2021 & 2031F |
3.3 Ireland Neuroprotective Agents Market - Industry Life Cycle |
3.4 Ireland Neuroprotective Agents Market - Porter's Five Forces |
3.5 Ireland Neuroprotective Agents Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 Ireland Neuroprotective Agents Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.7 Ireland Neuroprotective Agents Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 Ireland Neuroprotective Agents Market Revenues & Volume Share, By Distribution Cahnnel, 2021 & 2031F |
4 Ireland Neuroprotective Agents Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increase in prevalence of neurological disorders in Ireland |
4.2.2 Rising healthcare expenditure and focus on research and development in neuroprotective agents |
4.2.3 Growing awareness about the importance of neuroprotection in improving patient outcomes |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for approval of neuroprotective agents |
4.3.2 High cost associated with development and commercialization of neuroprotective drugs |
4.3.3 Limited availability of skilled healthcare professionals specializing in neurology |
5 Ireland Neuroprotective Agents Market Trends |
6 Ireland Neuroprotective Agents Market, By Types |
6.1 Ireland Neuroprotective Agents Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 Ireland Neuroprotective Agents Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 Ireland Neuroprotective Agents Market Revenues & Volume, By Anesthetics, 2021- 2031F |
6.1.4 Ireland Neuroprotective Agents Market Revenues & Volume, By Antagonists, 2021- 2031F |
6.1.5 Ireland Neuroprotective Agents Market Revenues & Volume, By Antidepressants, 2021- 2031F |
6.1.6 Ireland Neuroprotective Agents Market Revenues & Volume, By Cytokines, 2021- 2031F |
6.1.7 Ireland Neuroprotective Agents Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Ireland Neuroprotective Agents Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 Ireland Neuroprotective Agents Market Revenues & Volume, By Alzheimer's disease, 2021- 2031F |
6.2.3 Ireland Neuroprotective Agents Market Revenues & Volume, By Dementia, 2021- 2031F |
6.2.4 Ireland Neuroprotective Agents Market Revenues & Volume, By Epilepsy, 2021- 2031F |
6.2.5 Ireland Neuroprotective Agents Market Revenues & Volume, By Multiple sclerosis, 2021- 2031F |
6.2.6 Ireland Neuroprotective Agents Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Ireland Neuroprotective Agents Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 Ireland Neuroprotective Agents Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 Ireland Neuroprotective Agents Market Revenues & Volume, By Topical, 2021- 2031F |
6.3.4 Ireland Neuroprotective Agents Market Revenues & Volume, By Epidural, 2021- 2031F |
6.3.5 Ireland Neuroprotective Agents Market Revenues & Volume, By Intravenous, 2021- 2031F |
6.4 Ireland Neuroprotective Agents Market, By Distribution Cahnnel |
6.4.1 Overview and Analysis |
6.4.2 Ireland Neuroprotective Agents Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.4.3 Ireland Neuroprotective Agents Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
6.4.4 Ireland Neuroprotective Agents Market Revenues & Volume, By Drug Stores, 2021- 2031F |
6.4.5 Ireland Neuroprotective Agents Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
7 Ireland Neuroprotective Agents Market Import-Export Trade Statistics |
7.1 Ireland Neuroprotective Agents Market Export to Major Countries |
7.2 Ireland Neuroprotective Agents Market Imports from Major Countries |
8 Ireland Neuroprotective Agents Market Key Performance Indicators |
8.1 Number of clinical trials conducted for neuroprotective agents in Ireland |
8.2 Adoption rate of neuroprotective agents in neurological treatment protocols |
8.3 Research and development investment in neuroprotective agents in Ireland |
9 Ireland Neuroprotective Agents Market - Opportunity Assessment |
9.1 Ireland Neuroprotective Agents Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 Ireland Neuroprotective Agents Market Opportunity Assessment, By Application, 2021 & 2031F |
9.3 Ireland Neuroprotective Agents Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 Ireland Neuroprotective Agents Market Opportunity Assessment, By Distribution Cahnnel, 2021 & 2031F |
10 Ireland Neuroprotective Agents Market - Competitive Landscape |
10.1 Ireland Neuroprotective Agents Market Revenue Share, By Companies, 2024 |
10.2 Ireland Neuroprotective Agents Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here